Interview: Steve Bates – CEO, BioIndustry Association (BIA), UK
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
Address: 7th Floor, Southside
105 Victoria Street
London
SW1E 6QT
UK
Tel: +44 (0)20 7630 2180
Web: http://www.bioindustry.org/home/
The UK BioIndustry Association, the BIA, is the trade association for innovative enterprises involved in UK bioscience. Members include start-up, emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector.
The BIA works to further the interests of members and the industry – nationally and internationally. Our heritage of innovation, enterprise and success dates back to our founding over 20 years ago.
Influencing Progress
Bioscience is a national priority for the UK. The BIA works to encourage and promote a financially sound and thriving bioscience sector within the UK economy.
Our goal is to secure the UK’s position as a global hub and as the best location for innovative research and commercialisation, to help enable our world-leading research base to deliver healthcare solutions that can truly make a difference to people’s lives.
Lobbying is a core BIA strength. We provide a strong, unified, relentless voice for bioscience to stakeholders — including government, politicians, the media and patient advocate groups — to address the critical issues our members face and to push for progress. We educate policy makers about the needs of our members and advocate for legislation and policies essential to their growth and success.
Enabling Connections
Collaboration is key to moving bioscience forward. To support and enhance collaboration, the BIA brings together organisations from across the life sciences industry. This includes service providers, valued not only for the vital functions they serve in the sector, but also for their business acumen, expert guidance and industry connections.
The BIA hosts events throughout the year where members and others from the sector can learn, discuss, debate and network.
BIA Advisory Committee meetings connect peer groups to engage in debate and develop solutions to shared issues and challenges.
The BIA also keeps members connected and updated via regular communications. In addition, the BIA provides a host of other business development and business support services to enhance the value of membership. We facilitate introductions to other BIA members, provide meeting spaces at our central London office, offer member-only discounts to BIA and selected third-party events and also with suppliers.
In fulfilling its mission, the BIA aims to:
1 Offer a wide range of member services and benefits to the satisfaction of the membership
2 Represent the needs of the industry and its members on important issues
3 Promote best practice within the industry
4 Facilitate industry growth and maturity, positioning the UK as a leading world player in bioscience
5 Campaign for the best possible environment for innovative bioscience research
6 Communicate the benefits of innovative bioscience technologies
7 Maintain its role as the Association of choice for membership representation and communication on innovative bioscience issues
The BIA operates an active public affairs programme, a well-developed conference and and seminar programme, trade missions, regular publications for internal and external audiences, plus a series of committees whose interests range from regulatory affairs and intellectual property to personnel and finance and taxation. Networking and technology-transfer opportunities for members and others with an interest in the sector ensure that every avenue is explored in the support of UK bioscience.
Steve Bates, CEO of the UK BioIndustry Association (BIA) for over five years, shares the importance of the UK’s status as a global life science hub, the long-term government actions…
The UK has got around half of the public biotech companies and 21% of all entrepreneurial bioscience companies in Europe. From your perspective, can you explain what the key success…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here